For virologically suppressed adult patients with HIV-1. See Full Indication.
JULUCA | Clinical Trials
Trial Design & Baseline Characteristics
SWORD 1 & 2: Two identically designed, Phase 3 trials in treatment-experienced, virologically suppressed adult patients with HIV-1
Virologic Suppression & Resistance Results
Pooled virologic response and resistance results through 148 weeks
Adverse Reactions
Adverse reactions and rates of discontinuation due to adverse events at 148 weeks
Patient-Reported Outcomes
Learn about rates of treatment satisfaction and symptom distress through 148 weeks
Lipid and Fracture Data and a DEXA Substudy
Learn more about effect on lipids, incidence of fractures, and change in BMD with JULUCA
BMD=bone mineral density; DEXA=dual-energy X-ray absorptiometry.
DGRWCNT210012